The European Medicines Agency (EMA) has recommended granting marketing authorization in the EU for brensocatib (Brinsupri, ...

If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis ...

If you receive a denial letter from your insurer, seek legal advice before appealing the decision, says a leading disability lawyer.

Panelists discuss how bronchiectasis is more common than previously thought, with growing awareness, research, and specialized centers improving diagnosis and treatment options, though challenges ...

In bronchiectasis, highly symptomatic patients have a greater risk of exacerbations and may benefit from long-term macrolide treatment.

British scientists have found the first-ever treatment for bronchiectasis, the disease Pope Francis was hospitalized with in the weeks prior to his death, The Telegraph reported. Francis suffered from ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Bronchiectasis ...

Brinsupri is an oral inhibitor of dipeptidyl peptidase 1 and targets neutrophilic serine proteases, which mediate ...

NEW YORK, New York — Despite significant baseline differences, the disease progression and the outcomes at 5 years are similar in those with nontuberculous mycobacteria (NTM) infection relative to ...

A bronchiectasis action management plan for children significantly improved flu vaccine uptake but not the level of unscheduled doctor visits.